整合分子预后分类器可改进非小细胞肺癌的常规分期
研究将14基因分子预后分类器整合入第八版TNM分期,构建TNMB分期系统,并在加州大学旧金山分校321例患者中开发、在1373例多中心独立队列中验证。与第八版TNM相比,TNMB的净重分类改善为0.33(95%CI 0.24-0.41),相对综合判别改善为22.1%(95%CI 8.8%-35.3%),重分类校准统计量由39降至21。
要点
- TNMB分期将14基因分子预后分类器与第八版TNM分期整合。
- TNMB较第八版TNM的净重分类改善为0.33(95%CI 0.24-0.41)。
- TNMB较第八版TNM的相对综合判别改善为22.1%(95%CI 8.8%-35.3%)。
核心结论
- 整合分子预后分类器较常规分期显著改进高危患者识别与生存预测。
- TNMB分期系统可能通过更有效地应用辅助治疗改善早期疾病生存。
研究设计与样本
- 利用加州大学旧金山分校321例NSCLC患者数据开发TNMB分期系统。
- 在1373例独立多中心队列中验证TNMB分期系统。
- 采用重分类指标比较TNMB与第七版、第八版TNM分期的实施效果。
主要发现
- TNMB较第八版TNM的净重分类改善为0.33(95%CI 0.24-0.41)。
- TNMB较第八版TNM的相对综合判别改善为22.1%(95%CI 8.8%-35.3%)。
- TNMB的重分类校准统计量由39降至21,观察与预测生存一致性改善。
- 第七版TNM的净重分类改善为0.01(95%CI -0.04至0.03),相对综合判别改善为2.1%(95%CI -5.8至9.9)。
- 第八版TNM的净重分类改善为0.03(95%CI 0.00至0.06),相对综合判别改善为-2.5%(95%CI -17.6至12.4),重分类校准统计量由23升至25。
临床怎么用
- 作者认为TNMB分期系统可能通过更有效地应用辅助治疗改善早期疾病生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite adoption of molecular biomarkers in the management of NSCLC, the recently adopted eighth edition of the TNM staging system utilized only clinicopathologic characteristics and validated improvement in risk stratification of early-stage disease has remained elusive. We therefore evaluated the integration of a clinically validated molecular prognostic classifier into conventional staging. METHODS: A novel staging system, the TNMB (with the B denoting biology) system, which integrates a 14-gene molecular prognostic classifier into the eighth edition of the TNM staging system, was developed by using data from 321 patients with NSCLC at the University of California, San Francisco. The TNMB staging system was subsequently validated in an independent, multicenter cohort of 1373 patients, and its implementation was compared with adoption of the seventh and eighth edition staging systems utilizing metrics of reclassification. RESULTS: Compared with staging according to the eighth edition of the TNM system, the TNMB staging system enhanced the identification of high-risk patients, with a net reclassification improvement of 0.33 (95% confidence interval [CI]: 0.24-0.41). It better predicted differences in survival, with a relative integrated discrimination improvement of 22.1% (95% CI: 8.8%-35.3%), and it improved agreement between observed and predicted survival, with a decrease in the reclassification calibration statistic of from 39 to 21. The seventh and eighth editions failed to change the net reclassification improvement (0.01 [95% CI: -0.04 to 0.03] and 0.03 [95% CI: 0.00 to 0.06], respectively) or relative integrated discrimination improvement (2.1% [95% CI: -5.8 to 9.9] and -2.5% [95% CI: -17.6 to 12.4], respectively); in addition, the eighth edition worsened calibration, with an increase in the reclassification calibration statistic from 23 to 25. CONCLUSIONS: Incorporation of a molecular prognostic classifier significantly improved identification of high-risk patients and survival predictions compared with when conventional staging is used. The TNMB staging system may lead to improved survival of early-stage disease through more effective application of adjuvant therapy.
引用
- Kratz JR, Haro GJ, Cook NR, et al. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging. J Thorac Oncol. 2019. PMID: 30959120. doi:10.1016/j.jtho.2019.03.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。